Clinical Trials & Research

Scientists have recently tried to explain the factors that could be responsible for the recent outbreaks of coronavirus disease 2019 (COVID-19) in Israel. Their observations reveal that the prevalence of the more infectious delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and waning vaccine efficacy results in the outbreaks. As preventive interventions, they

Researchers worldwide hypothesized that the development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could help to reduce transmission and help to lower the mortality rate. The vaccines developed against coronavirus disease 2019 (COVID-19) had to undergo several clinical trials before they could be considered safe for human use. Patients of various age

The ongoing coronavirus disease 2019 (COVID-19) pandemic has caused an economic and healthcare crisis. COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a positive-stranded and RNA virus belonging to the family Coronaviridae. This virus is highly virulent and has already claimed more than 4.66 million live worldwide. Study: Neutralizing Monoclonal Antibodies

In a report currently available on the bioRxiv* preprint server, scientists from the USA have demonstrated that immunity induced by mRNA-based coronavirus disease 2019 (COVID-19) vaccines in previously severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected people has the highest robustness and durability with cross-reactivity against different viral variants. Study: Differential antibody dynamics to SARS-CoV-2 infection

Immunocompromised patients benefit from receiving the two-dose Pfizer-BioNTech vaccine, according to a new study available on the preprint server medRxiv*. The clinical trial showed that about 72.2% of immunocompromised patients had detectable antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While the vaccine was safe and effective, immunocompromised patients developed fewer antibodies than patients

Recent data indicates that individuals are experiencing coronavirus disease 2019 (COVID-19) symptoms long after clearing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which suggests the virus has profound consequences to host cells. Study: SARS-CoV-2 triggers DNA damage response in Vero E6 cells. Image Credit: Festa/ Shutterstock RNA viruses, such as SAR-CoV-2, are renowned for

A new study by the ICTA-UAB establishes that the population density of hunter-gatherer groups was reduced where they depended heavily on meat to survive. Hunter-gatherer populations with a strong seasonal dependence on meat in their diets had fewer people per square kilometer than those that had abundant plant foods throughout the year. This new result

Sandrine V. Pierre, Ph.D., associate professor of biomedical sciences at the Marshall University Joan C. Edwards School of Medicine and interim director of the Marshall Institute for Interdisciplinary Research (MIIR), has been awarded a Research Project Grant (R01), one of the most competitive grants issued by the National Institutes of Health (NIH). Pierre was awarded

A team of international scientists has recently assessed the strategies adopted by the Nordic countries to curb the trajectory of the coronavirus disease 2019 (COVID-19) pandemic. Their findings reveal that to decrease the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is important to minimize the number, size, and duration of transmission clusters

GAITHERSBURG, Md., Sept. 8, 2021 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in a Phase 1/2 study to evaluate the safety and immunogenicity of a combination vaccine using Novavax’ seasonal influenza and COVID-19 vaccines. The

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the virus that causes coronavirus disease 2019 (COVID-19) – is not associated with neuroaxonal damage, according to a new study from researchers in Germany. Neurological symptoms have been observed in about one-third of coronavirus cases. However, the full extent of the virus’s impact on the brain

LA ROCHELLE, France. Sept 6, 2021 – Valbiotis, a French research and development company committed to scientific innovation for preventing and combating metabolic diseases, announces that it has completed the recruitment of 120 volunteers for the Phase II HEART clinical study at the beginning of September 2021, in accordance with the schedule announced by the

Since it was first detected in December 2019 in Wuhan, China, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the virus that causes coronavirus disease 2019 (COVID-19) – has infected over 217 million people worldwide. To date, this has led to over 4.56 million deaths worldwide. The COVID-19 pandemic continues to affect more

SAN FRANCISCO, Sept. 3, 2021.  Quantum Leap Healthcare Collaborative, the sponsor of the I-SPY COVID Trial, today announced that the Famotidine Celecoxib arm has been dropped from the trial due to futility, based on the low likelihood of success. The Famotidine Celecoxib combination was chosen for testing because of their anti-histamine and anti-inflammatory mechanism of

Don and Karen Cohn have given $2.5 million to create the Don and Karen Cohn Chancellor’s Endowed Chair in Neurosurgery at University of California San Diego School of Medicine. The gift will support excellence in research, education and clinical care in the field of neurological surgery. Alexander Khalessi, MD, neurosurgeon at UC San Diego Health,

MANHASSET, N.Y., Sept. 2, 2021. As part of a new National Institutes of Health (NIH) coronavirus disease 2019 (COVID-19) vaccine clinical trial, The Feinstein Institutes for Medical Research – the science arm of Northwell Health – delivered its first set of extra shots to eligible New York patients with an autoimmune disease. An estimated 8

Ziath, a leading supplier of equipment, software and consumables to simplify your sample management process, offers a range of CryzoTraq™ tubes designed for high integrity cryogenic storage of biological specimens at temperatures down to -196°C. Image Credit: Ziath Ltd Related Stories CryzoTraq™ 2D barcoded tubes are manufactured in a Class 7 cleanroom using medical-grade polypropylene. 

MADRID, Aug. 31, 2021. Results from a new human clinical study demonstrate a significant capacity for Pharmactive’s potent all-natural affron standardized saffron extract to promote restorative sleep. The ingredient showed its effect in a single, low dose taken just one hour before bedtime, making affron a natural ingredient that is very easy to consume. Moreover,

Since the COVID-19 pandemic reached the United States in early 2020, scientists have struggled to find laboratory models of SARS-CoV-2 infection, the respiratory virus that causes COVID-19. Animal models fell short; attempts to grow adult human lungs have historically failed because not all of the cell types survived. Undaunted, stem cell scientists, cell biologists, infectious

ABBOTT PARK, Ill., Aug. 27, 2021.  Abbott today announced results of the landmark GUIDE-HF clinical trial, a 1,000 patient randomized study designed to assess the benefits of the CardioMEMS HF System in people living with NYHA Class II, III and IV heart failure. Data adjusted for the impact of COVID-19 show a strong reduction in

Until now, patients with heart failure with preserved ejection fraction – the most common type of heart failure in the elderly – have had no access to evidenced-based treatments. For the first time, a large clinical trial led by Prof. Dr. Stefan Anker from Charité – Universitätsmedizin Berlin has identified a drug which has a

CINCINNATI, Aug. 26, 2021.  Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced dosing of the first patient on August 17, 2021 in the AT-100 (rhSP-D) Phase 1b trial in mechanically-ventilated COVID-19 patients. The clinical

As the election to recall California Gov. Gavin Newsom approaches, abortion-rights groups are warning that Californians’ right to an abortion is on the ballot. Newsom, a Democrat, himself tweeted that “abortion access” is at stake. “There’s no question that if a Republican is elected, access to abortion in California will be restricted,” Jodi Hicks, president

NEW YORK, Aug. 24, 2021. Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that it has enrolled and randomized over 25% of the planned 450 patients for its Phase 3 ORA-D-013-2 trial of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes

After Russell Jordan sent a stool sample through the mail to the microbiome company Viome, his idea of what he should eat shifted. The gym owner in Sacramento, California, had always consumed large quantities of leafy greens. But the results from the test — which sequenced and analyzed the microbes in a pea-sized stool sample

Monday, August 23, 2021. Randomized, double-blind, placebo-controlled study did not meet the primary endpoint: change in the total Mayo score at week eight, relative to placebo Izencitinib was well-tolerated and safety data were consistent with expectations for this gut-selective pan-JAK inhibitor DUBLIN and SOUTH SAN FRANCISCO, Calif., /PRNewswire/ — Theravance Biopharma, Inc. (“Theravance Biopharma” or

People struggling to motivate themselves to engage in activities that are good for them should tap into their imagination to visualize themselves carrying out the activity, according to new research from The University of Western Australia. Dr Julie Ji. Image Credit: The University of Western Australia Related Stories Forrest Fellow Dr Julie Ji and her

London UK and Tübingen, Germany / Boston, USA -16 August 2021 Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone Data demonstrates high protective efficacy of second-generation lead candidate, CV2CoV, in animal model during SARS-CoV-2 challenge study Neutralizing capacity